Physiogenex will be present at the 28th Annual meeting of the Asian Pacific Association for the Study of the Liver, on February 23rd, 2019.
Dr. François Briand, our Director of Research and Business Development, will present 2 posters dealing with our innovative NASH models:
ID 461: ”The benchmarks Obeticholic Acid and Elafibranor show variable effects on NASH and hepatic fibrosis in diet-induced or chemically-induced animal models”.
ID 603: “GLP-1 receptor agonists reduce liver inflammation in a 3-week Non Alcoholic SteatoHepatitis Mouse Model”.
Dr. Briand will be happy to discuss with you about your preclinical NASH project, explore it and share with you his expertise. Please Contact us to set-up an appointment.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.